Pepetide receptor radionuclide therapy (PRRT)
Treatment with Lutetium-octreotate
Pepetide receptor radionuclide therapy (PRRT)
Home
Welcome on the website about treatment with Lutetium-octreotate.
Procedure prior to therapy
Rules after therapy
Since patients are radioactive, they will have to follow certain rules when they leave hospital.
Side effects
The side effects mentioned here apply to treatment with Lutetium-octreotate.- Treatment
Treatment diagram during and after treatment 
For physicians
Information for referring physicians
Introduction
Lutetium-octreotate is a radioactive labelled peptide which can be used in radiation therapy.
Therapy
Each patient is given therapy 4 times with an interval of 6 to 10 weeks. Most often the interval is 9 weeks.
General information
General information for patients receiving treatment at the department of Nuclear Medicine
Results
Patient information
Information for patients (“informed consent” forms) can be found in these PDF files.
Contact
If you have any questions or remarks, you can send us an email.